High impact
Durvalumab (Imfinzi®)
BCBS Tennessee·Effective Sep 30, 2026
This is a new medical policy establishing coverage criteria and prior authorization requirements for Durvalumab (Imfinzi®) across multiple cancer indications including NSCLC, SCLC, biliary tract, hepatocellular carcinoma, endometrial, bladder, and gastric cancers. The policy specifies required genetic/molecular testing documentation, treatment combinations, disease stages, and 6-month authorization periods. CRITICAL: This policy is marked 'Do Not Implement until 9/30/26' and is not yet effective.